MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients

Xiaomei Wang1,2, Xiaoyu Wen1, Jingjing Zhou1, Yue Qi1, Ruihong Wu1, Yao Wang1, Yiwen Kui1, Rui Hua1, Qinglong Jin1*

1 Department of Hepatology, The First Hospital of Jilin University, Changchun, China, 2 Key Laboratory of Zoonosis Research, Ministry Education, Changchun, China

* qinglongjin01@163.com.

Abstract

Recently, there is ample evidence suggesting the important role of microRNAs (miRNAs) in autoimmune diseases via modulating B cells function. Primary biliary cholangitis (PBC) is a progressive immune-mediated liver disease with unclear pathogenic mechanism. Whether the miRNA in peripheral B cells of PBC involve the mechanisms of pathology and progression is not known. The present study explores miRNA deregulation in peripheral B-cell of PBC from stage I to IV and healthy controls. Peripheral B cells were obtained from 72 PBC patients (stage I, n = 17; stage II, n = 23; stage III, n = 16; stage IV, n = 16) and 15 healthy controls. Initially, in a discovery study, miRNA array analysis was performed, subsequently, in a validation study, quantitative PCR was used to investigate miRNA expression profile in B cells of PBS patients compared to healthy controls. Based on bioinformatics analysis, we identified the potential biological processes and significant signaling pathways affected by these microRNAs, and generated the microRNA–gene network. The discovery study identified 558 miRNAs differentially expressed in B cells of PBC patients compared to controls. Interestingly, among all differentially expressed miRNAs, hsa-miR-223-3p and hsa-miR-21-5p were the only miRNAs that showed consistent and significant down-regulation from stage I to stage III of PBC. Bioinformatics showed that potential target genes of both miRNAs involved in migration, cell differentiation, apoptosis, and signal transduction pathways. In conclusion, our results suggest that the expression profiles of miRNA in peripheral B cells of PBC patients are closely associated with the disease progression, especially the down-regulation of hsa-miR-223-3p and hsa-miR-21-5p. Taken together, our study offers novel perspectives on the role of miRNAs in PBC pathogenesis.

Introduction

Primary biliary cholangitis (PBC) is a progressive immune-mediated liver disease characterized by damage of the small intrahepatic bile ducts, resulting in perportal inflammation, fibrosis and cirrhosis. The disease mainly affects mostly middle-aged women [1]. Etiologically, PBC
is believed to result from a combination of a genetic and environmental factors[2]. The treatment of PBC is ursodeoxycholic acid (UDCA) in the past 30 years and obeticholic acid (OCA) approved in May 2017 by FDA, which increases the transplant-free survival, especially when starts early in the course of disease[3]. However, a substantial proportion (about 40%) of PBC patients does not respond to ursodeoxycholic acid treatment. Therefore, identifying novel cellular molecules and mechanisms contributing to PBC pathogenesis are needed to open new insights for novel treatments.

 microRNAs (miRNAs) are small noncoding RNA (19 to 24 nucleotides) that can bind to complementary sites on the target mRNA and hence alter its transcription and translation [4–6]. Currently, more than 2500 mature human miRNAs are listed in the miRBase database [7]. miRNAs affect various important cell functions such as cell division, differentiation, apoptosis, carcinogenesis, and immune function [8]. Different pathological conditions including autoimmune diseases, cancers, and liver diseases have different miRNA expression profiles [9–11]. Furthermore, evidence is growing that miRNA expression profiles are different among different liver diseases and some microRNA may relate to the progression stage of liver disease[12].

 Although some studies focused on global miRNA expression profiles either in liver biopsies or peripheral blood mononuclear cells (PBMC) of PBC patients [13, 14], the molecular mechanism and etiology of this enigmatic autoimmune disease is still not fully known. The transition from innate immunity to acquired immunity is followed by the presence of autoreactive T and B cells, which are involved in high titer serum anti-mitochondrial antibodies (AMA) and an autoimmune-mediated destruction of small intrahepatic bile ducts [15]. There have been no prior studies of miRNA expression patterns in B cells from different pathological stages of PBC patients. In the current study we investigated for the first time the expression profile of miRNAs in B cells, producer of AMA, of PBMC obtained from Chinese patients with different pathological stages of PBC. This approach might reveal novel mechanistic insights of miRNAs role in PBC pathogenesis and identifying their gene targets.

**Materials and methods**

**PBC patients and healthy controls**

The study involved 87 subjects (72 PBC patients and 15 healthy controls) recruited from The First Hospital, Jilin University (Changchun, China) between 2014 and 2016. The PBC patients were diagnosed according to the AASLD Practice Guideline[16]. The diagnosis of cirrhosis was based on liver biopsy and all patients were treatment naive. Exclusion criteria included individuals infected with HBV, HCV and HDV, or other inflammatory diseases, patients presented with rheumatoid arthritis, diabetes, autoimmune hepatitis, hypertension. The healthy controls had no medical history of any liver disease, autoimmune diseases or other diseases. The experimental protocol was approved by the Ethics Committee of the First Hospital of Jilin University. An informed written consent was obtained from each patient.

Based on histologic lesions, PBC progression was divided into four stages. Stage I is characterized by portal inflammation with or without bile duct involvement. Stage II is characterized by the gradual increase of periportal lesions extending into the hepatic parenchyma. Stage III is characterized by a alteration of the hepatic architecture with numerous fibrous septa. Cirrhosis with the existence of regenerative nodules defines stage IV[17]. Accordingly, among the 72 PBC patients involved in this study, there were 17, 23, 16 and 16 patients with stages I, II, III and IV, respectively. The healthy controls were age and gender matched with the PBC patients. Detailed clinical information is shown in Table 1.
B cell collection and RNA isolation

Venous blood samples (20 ml) were collected in EDTA-treated tubes from all subjects. Next, we applied density gradient centrifugation (Histopaque®-1077, Sigma-Aldrich, Saint Louis, USA) to isolate the PBMCs. B cells were separated from PBMCs using CD19 microbeads (Miltenyi, Cologne, Germany). Purity of the CD19+ B cells population was assessed by fluorescence-activated cell sorting (FACS) and was found to be 92%–97%. Total RNA was harvested from B cells using TRIzol (Invitrogen, Carlsbad, USA) according to the manufacturer’s instructions. In discovery study, a total of 39 RNA samples obtained from 32 PBC patients and 7 healthy controls were used for miRNA array analysis, while in validation study, additional 48 RNA samples obtained from 40 PBC and 8 healthy controls were used.

MicroRNA array analysis

The RNA samples from B cells isolated from PBC patients or healthy control were labeled using a miRCURY™ Array Power Labeling kit (Exiqon, Vedbaek, Denmark). Next, the labeled RNA was hybridized on a miRCURY™ LNA Array (v.18.0, Exiqon). Array slides were scanned using an Axon GenePix 4000B Microarray Scanner (Axon Instruments, Foster, USA). Data were extracted from scanned images using GenePix Pro 6.0 (Axon Instruments). All the microarray analysis was performed by the Exiqon miRNA Expression Profiling service (Kangchen Bio-tech, China).

Quantitative real-time polymerase chain reaction (qPCR)

We used qPCR to validate the differentially expressed miRNAs identified in the validation study of miRNA arrays. Total RNA extracted from PBMCs was used to synthesize cDNA using miRNA-specific, stem-loop reverse transcription (RT) primers and reagents from a MMLV Reverse Transcriptase kit (Epicentre, Madison, USA), following the manufacturer’s protocol. Next, we performed qPCR with ViiA 7 Real-time PCR System (Applied Biosystems, Foster, USA), and 2×SYBR-Green PCR master mix (Arraystar, Rockville, USA) according to the manufacturer’s instructions. We used the following primers: hsa-miR-223-3p F: 5‘GGGGTGTCAGTTTGTCAAA3’, R:5‘CAGTGCGTGTCGTGGAGT3’; hsa-miR-21-5p F: 5‘GGGGGGTAGCTTATCAGACTG3’, R:5‘CAGTGCGTGTCGTGGAGT3’. All reactions were performed in triplicate. The expression level of each miRNA was calculated relative to U6 RNA. The relative expression level of each miRNA was calculated using the equation $2^{-\Delta \Delta Ct}$.

---

### Table 1. Clinical characteristics of PBC patients and healthy controls.

| Stage I (n = 17) | Stage II (n = 23) | Stage III (n = 16) | Stage IV (n = 16) | Control (n = 15) | $P$ value |
|------------------|-------------------|-------------------|------------------|-----------------|-----------|
| Gender (Female/male) | 16/1 | 21/2 | 16/0 | 16/0 | 13/2 | 0.11 |
| Age | 53.1±3.8 | 54.8±4.9 | 51.7±3.4 | 52.7±5.6 | 48.0±4.5 | 0.24 |
| AST | 72.9±18.7 | 78.6±11.4 | 83.3±24.4 | 97.6±24.4 | 26.0±2.9 | 0.46 |
| ALT | 69.2±26.1 | 88.8±12.2 | 83.4±12.2 | 84.2±30.7 | 27.0±5.5 | 0.16 |
| GGT | 344.7±104.5 | 445.6±102.4 | 460.6±144.0 | 466.1±139.1 | 25.0±3.4 | 0.20 |
| ALP | 290.2±73.2 | 300.7±44.1 | 358.2±142.6 | 212.1±65.6 | 56.3±11.8 | 0.001 |
| ALB | 39.1±1.6 | 37.7±1.0 | 35.7±1.0 | 27.8±3.8 | 47.0±3.2 | 0.024 |
| TB | 16.5±5.6 | 21.1±6.9 | 21.5±7.8 | 61.3±10.4 | 15.4±3.2 | 0.01 |

AST, aspartate transaminase; ALT, alanine aminotransferase; GGT, gamma-glutamyl-transpeptidase; ALP, alkaline phosphatase; ALB, albumin; TB, total bilirubin. PBC, primary biliary cholangitis. N/A, not available.

https://doi.org/10.1371/journal.pone.0184292.t001
Bioinformatic analysis of differentially expressed miRNAs

To evaluate functions of candidate miRNAs of PBC patients, target genes prediction were performed using the TargetScan database (http://www.targetscan.org/vert_70/)[18].

The functional annotation of target genes were performed using the DAVID, v6.7 (https://david.ncifcrf.gov/summary.jsp) [19]. DAVID provides functional annotation of a gene list based on gene ontology (GO) terms, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway as well as the BioCarta pathway databases. [13].

Statistical analysis

For the discovery study, the non-normally distributed continuous variables of differentially expressed miRNAs between cases and controls were compared by Mann-Whitney U test. Different miRNAs were compared using significant analysis and false discovery rate (FDR) analysis. The FDR was calculated to correct the p-value. FDR ≤ 0.2 indicated smaller errors in judging p-values.

For the validation study, one-way ANOVA was applied to extract differentially expressed miRNAs in qPCR among the four groups of PBC and controls. P-values of less than 0.05 were considered statistically significant.

Results

Patient population

Demographic characteristics and blood biochemical parameters of PBC patients with different 4 stages of the disease as well as healthy controls were summarized in Table 1.

miRNA expression profile of B cell in PBC and controls

Expression profiles of miRNAs obtained from blood B cell of PBC patient and controls were compared using miRNA arrays. After normalization of the raw data and random variance model, we found a total of 558 miRNAs that differentially expressed between the PBC patients and controls. In particular, this analysis identified 266 up-regulated microRNAs (>2-fold) and 292 down-regulated microRNAs (<0.5-fold) in PBC patients compared to controls.

Moreover, we found differentially expressed miRNAs even among the four stages of PBC, suggesting the association between miRNA expression profile and the progression stage of the disease. (Table 2). Notably, more advanced disease-stage showed more differentially expressed miRNA compared to less advanced disease-stage.

Table 2. Number of differentially expressed miRNAs among groups.

| Compare        | Stage I | Stage II | Stage III | Stage IV | Stage I | Stage II | Stage III | Stage IV |
|----------------|---------|----------|-----------|----------|---------|----------|-----------|----------|
| Control vs     | 212     | 285      | 236       | 241      | 77      | 0        | 2         | 131      |
|                | 231     | 300      | 292       | 288      | 110     | 14       | 8         | 104      |
|                | 443     | 585      | 528       | 529      | 187     | 14       | 10        | 235      |

https://doi.org/10.1371/journal.pone.0184292.t002
Differential expression of miRNAs in B cells from four PBC stages

Among all 558 differentially expressed miRNAs identified in discovery study, hsa-miR-223-3p and hsa-miR-21-5p were the only miRNAs showed consistent and significant down-regulation from stage I to stage III, (Fold Change < 0.5, p < 0.05), while the expression levels of both miRNAs were not different between stages III and V (Table 3). This indicates that the more advanced PBC-stage the more inhibition of hsa-miR-223-3p and hsa-miR-21-5p expression.

Validation of miRNA array results by qPCR

To validate the differential expression of hsa-miR-223-3p and hsa-miR-21-5p observed in discovery study of miRNA array analysis, qPCR were performed as a confirmatory method. Validation of the miRNA results was conducted in additional 48 samples (40 PBC patients and 8 healthy controls), which are different from the initial 39 RNA samples used in discovery study. Indeed, the relative expression of hsa-miR-223-3p, hsa-miR-21-5p was significantly different between PBC patients and controls. Furthermore, the expression of both miRNA was also different among stages I, II and III of PBC stages, confirming the results obtained from miRNA array analysis of discovery study (Fig 1).

Microarray-based GO analysis and pathway analysis

We predicted the target genes of hsa-miR-223-3p and hsa-miR-21-5p using online search algorithms for target prediction (TargetScan, http://www.targetscan.org). There are 412 target genes for hsa-miR-223-3p and 382 target genes for hsa-miR-21-5p. Number of B cell-related predicted target genes of hsa-miR-223-3p and hsa-miR-21-5p were 10, 12, respectively. Target genes were annotated using DAVID v6.7 (https://david.ncifcrf.gov/summary.jsp).

For these putative target genes, GO analysis and KEGG pathway analysis were applied to display the miRNA–gene regulatory network. The most significant GO categories for the target genes of hsa-miR-21-5p and hsa-miR-223-3p are regulation of macromolecule metabolic process, regulation of transcription and regulation of cell migration (Table 4). Results in GO biological process(BP) indicated that 6 functions matched ranking score ≥ 2.0 were identified in PBC.

Also, these predicted target genes were entered in gene set enrichment analysis (GSEA) using KEGG database. The top 10 canonical KEGG pathways were shown in Fig 2, including FoxO, TGFβ and MAPK signaling pathways, and transcriptional misregulation in cancer.

Identification of microRNA–B-cell related gene network

Based on the putative target B cell function related genes of hsa-miR-21-5p and hsa-miR-223-3p, the microRNA gene regulatory network was constructed to outline the interactions of both microRNAs and their targets. As shown in Fig 3, two microRNAs (miR-223-5p, miR-21-5p) were in the center of the microRNA–gene network. There were mutual 4 target genes related B cell function of miR-223-5p, miR-21-5p, they were TGFB1R2, MEF2C, FOXP1 and

### Table 3. Expression of miR-223-3p and hsa-miR-21-5p in peripheral blood B cells of PBC patients and controls.

| miRNA         | Control Mean±SE | Stage I Mean±SE | Stage II Mean±SE | Stage III Mean±SE | Stage IV Mean±SE | Expression | p value |
|---------------|-----------------|-----------------|-----------------|-------------------|------------------|------------|---------|
| hsa-miR-223-3p| 44.62±11.65     | 16.31±3.68      | 7.05±1.97       | 2.37±1.12         | 1.62±0.89        | down       | <0.001  |
| hsa-miR-21-5p | 52.45±2.80      | 17.20±2.59      | 6.46±1.04       | 2.03±0.25         | 1.86±0.33        | down       | <0.001  |

https://doi.org/10.1371/journal.pone.0184292.t003
These target genes are related to B cell function, such as B-cell differentiation, activation, receptor signaling pathways, and homeostasis.

Discussion

Recently, there is ample evidence suggesting the important role of miRNAs in autoimmune diseases [20, 21]. Since PBC is a model of autoimmune disease, but the pathogenic mechanism is not been full understood. Therefore, in the current study we aimed to investigate the association between miRNAs expression profile in peripheral B cells and the progression of PBC. B cells contributed in initiating liver inflammation, cyst formation and salivary gland pathology in a PBC mouse model, illustrating a critical role for B cells in modulating specific organ pathology [22].

Both discovery and validation studies of current investigation confirmed the significant association of the expression profile of the two miRNAs (hsa-miR-223-3p and hsa-miR-21-5p).
with PBC. More importantly, the expression levels of hsa-miR-223-3p and hsa-miR-21-5p were not only associated with PBC compared to healthy controls, but they were also significantly correlated to the progression-stage of PBC. The expression levels of both miRNA were decreased significantly with progression from early to advanced clinical stages.

In chronic lymphoid leukemia (CLL), the expression of hsa-miR-223-3p in B cells significantly decreases with the progression from early to advanced clinical stages [23]. Our observations and Zhou et al., results suggest that hsa-miR-223-3p might play an important role in the pathogenesis of B cell-related diseases [23]. Additionally, hsa-miR-223-3p was implicated in the autoimmune disease ulcerative colitis [24]. Taken together, hsa-miR-223-3p can be involved in the pathogenesis and progression of autoimmune diseases, including PBC. Future in vivo and in vitro mechanistic studies are needed to elucidate this issue.

Hsa-miR-21-5p is associated with tumors in several organs [25] and several liver diseases including nonalcoholic steatohepatitis [26], drug-induced liver injury [27], and hepatocellular carcinoma [28, 29]. However, the relationship between hsa-miR-21-5p and autoimmune disease has not been elucidated yet. Thus, our study is the first to suggest a possible link between hsa-miR-21-5p and PBC. Also, future in vivo and in vitro mechanistic studies are needed to elucidate the role of hsa-miR-21-5p in autoimmune diseases, in particular PBC.

In this study, GO analysis was used to obtain insights into the molecular function and biological processes of our identified target genes of hsa-miR-223-3p and hsa-miR-21-5p. This analysis highlighted the possible role of both miRNA in modulating B cell functions, including biological processes regulated by the two differentially expressed miRNAs included B-cell signal transduction, cell differentiation, cell migration, and apoptosis in GO categories.

On the other hand, KEGG pathways analysis was performed to further investigate the relationship between the two downregulated miRNAs and PBC pathogenesis. Several signaling pathways previously proposed to impact PBC pathogenesis were also identified as top candidates in our study such as TGF-β1 signaling, and MAPK signaling[30–32]. Again, further
studies are needed to determine how the down-regulation of hsa-miR-223-3p and hsa-miR-21-5p influence the progression of PBC.

This study identified 4 mutual target genes (TGFBR2, MEF2C, FOXP1 and RBPJ) related B cell function of miR-223-5p and miR-21-5p. Notably, TGFBR1 is a critical member in TGF-β1 signaling way. Interestingly, dominant negative TGFBR2 mice has been verified would develop serological and histological features resembling human primary biliary cholangitis[33, 34]. This suggests that miR-223-5p and miR-21-5p might regulate the progression of PBC via TGF-β1 signaling pathway in TGFBR2-dependent manner.

In conclusion, our results indicate that B cells from patients with various stages of PBC have different miRNA expression profiles. In particular, the down-regulation of hsa-miR-223-3p and hsa-miR-21-5p during the course of PBC progression would be a useful clinical biomarker. Taken together, our study offers novel perspectives on role of microRNAs in PBC pathogenesis, however, the precise mechanism needs further experimental investigation.

Supporting information

S1 Table. Differentially expressed miRNAs.
(XLSX)

S1 Fig. Heat map and hierarchical clustering of PBC vs. Control.
(TIF)
S2 Fig. Amplification plot of hsa-miR-21-5p.

(TIF)

S3 Fig. Amplification plot of hsa-miR-223-3p.

(TIF)

Author Contributions

Conceptualization: Qinglong Jin.

Data curation: Ruihong Wu, Yiwen Kui.

Formal analysis: Xiaomei Wang, Rui Hua.

Methodology: Qinglong Jin.

Project administration: Xiaoyu Wen, Jingjing Zhou, Yao Wang.

Resources: Xiaoyu Wen.

Supervision: Xiaomei Wang.

Validation: Yue Qi.

Writing – original draft: Xiaomei Wang.

Writing – review & editing: Qinglong Jin.

References

1. Smyk DS, Rigopoulou EI, Pares A, Billinis C, Burroughs AK, Muratori L, et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol. 2012; 2012:610504. https://doi.org/10.1155/2012/610504 PMID: 22693524.

2. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004; 127(2):485–92. PMID: 15300581.

3. Floreani A, Mangini C. Primary biliary cholangitis: Old and novel therapy. European journal of internal medicine. 2017. https://doi.org/10.1016/j.ejim.2017.06.020 PMID: 28669591.

4. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001; 294(5543):853–8. https://doi.org/10.1126/science.1064921 PMID: 11679670.

5. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001; 294(5543):858–62. https://doi.org/10.1126/science.1065062 PMID: 11679671.

6. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 294(5543):862–4. https://doi.org/10.1126/science.1065329 PMID: 11679672.

7. Gustafson D, Tyryshkin K, Renwick N. microRNA-guided diagnostics in clinical samples. Best practice & research Clinical endocrinology & metabolism. 2016; 30(5):563–75. https://doi.org/10.1016/j.beem.2016.07.002 PMID: 27923451.

8. Maes OC, An J, Sarojini H, Wang E. Murine microRNAs implicated in liver functions and aging process. Mech Ageing Dev. 2008; 129(9):534–41. https://doi.org/10.1016/j.mad.2008.05.004 PMID: 18651983.

9. Wolenski FS, Shah P, Sano T, Shinozawa T, Bernard H, Gallagher MJ, et al. Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage. J Appl Toxicol. 2016. https://doi.org/10.1002/jat.3558 PMID: 27397436.

10. Zekri AN, Youssef AS, El-Desouky ED, Ahmed OS, Lotfy MM, Nassar AA, et al. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol. 2016. https://doi.org/10.1007/s13277-016-5097-8 PMID: 27271989.

11. Salvoza NC, Klinzing DC, Goepz-Cervantes J, Baclig MO. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. PloS one. 2016; 11(4):e0153497. https://doi.org/10.1371/journal.pone.0153497 PMID: 27077736.
12. Van Keuren-Jensen KR, Malenica I, Courtright AL, Ghaffari LT, Starr AP, Metpally RP, et al. microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C. Liver International: official journal of the International Association for the Study of the Liver. 2016; 36(3):334–43. https://doi.org/10.1111/liv.12919 PMID: 26189820;

13. Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PloS one. 2013; 8(6):e66086. https://doi.org/10.1371/journal.pone.0066086 PMID: 23776611;

14. Qin B, Huang F, Liang Y, Yang Z, Zhong R. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013; 28(3):543–50. https://doi.org/10.1111/j.1440-1746.2012.07281.x PMID: 23173724;

15. Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol. 2008; 14(21):3328–37. https://doi.org/10.3748/wjg.v14.i21.3328 PMID: 18528930;

16. Silveira MG, Brunet EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010; 52(1):349–59. https://doi.org/10.1002/hep.23657 PMID: 20578151;

17. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, et al. Primary biliary cirrhosis. Hepatology. 2009; 50(1):291–308. https://doi.org/10.1002/hep.22906 PMID: 19554543;

18. Volinia S, Visone R, Galasso M, Rossi E, Croce CM. Identification of microRNA activity by Targets’ Reverse Expression. Bioinformatics. 2010; 26(1):91–97. https://doi.org/10.1093/bioinformatics/btp598 PMID: 19897564;

19. Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. PMID: 12734009;

20. Qu B, Shen N. miRNAs in the Pathogenesis of Systemic Lupus Erythematosus. Int J Mol Sci. 2015; 16(5):9557–72. https://doi.org/10.3390/ijms16059557 PMID: 25927578;

21. Furer V, Greenberg JD, Attur M, Abramson SB, Pillinger MH. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clinical immunology. 2010; 136(1):1–15. https://doi.org/10.1016/j.clim.2010.02.005 PMID: 20223711;

22. Moritoki Y, Tsuda M, Tsuneyama K, Zhang W, Yoshida K, Lian ZX, et al. B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3 c4 model of autoimmune cholangitis. Cellular immunology. 2011; 268(1):16–23. https://doi.org/10.1016/j.cellimm.2011.01.005 PMID: 21349950;

23. Zhou K, Yi S, Yu Z, Li Z, Wang Y, Zou D, et al. MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012; 53(6):1155–61. https://doi.org/10.3109/10428194.2011.642303 PMID: 22145984;

24. Gulamhusein AF, Juran BD, Lazaridis KN. Genome-Wide Association Studies in Primary Biliary Cirrhosis. Semin Liver Dis. 2015; 35(4):392–401. https://doi.org/10.1055/s-0035-1567831 PMID: 26676814;

25. Park SK, Park YS, Ahn JY, Do EJ, Kim D, Kim JE, et al. MiR-21-5p as a predictor of recurrence in young gastric cancer patients. Journal of gastroenterology and hepatology. 2016. https://doi.org/10.1111/jgh.13300 PMID: 26824989.

26. Takeuchi-Yorimoto A, Yamaura Y, Kanki M, Ide T, Nakata A, Noto T, et al. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Toxicol Lett. 2016. https://doi.org/10.1016/j.toxlet.2016.06.012 PMID: 27320964;

27. Park HK, Jo W, Choi HJ, Jang S, Ryu JE, Lee HJ, et al. Time-course changes in the expression levels of miR-122, -155, and -21 as markers of liver cell damage, inflammation, and regeneration in acetaminophen-induced liver injury in rats. J Vet Sci. 2016; 17(1):45–51. https://doi.org/10.4142/jvs.2016.17.1.45 PMID: 27051339;

28. Kamel RR, Amr KS, Afify M, Elhosary YA, Hegazy AE, Fahim HH, et al. Relation between microRNAs and Apoptosis in Hepatocellular Carcinoma. Open Access Maced J Med Sci. 2016; 4(1):31–7. https://doi.org/10.3889/oamjms.2016.038 PMID: 27275325;

29. Fiorino S, Bacchi-Reggiani ML, Visani M, Acquaviva G, Formenti A, Masetti M, et al. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol. 2016; 22(15):3907–36. https://doi.org/10.3748/wjg.v22.i15.3907 PMID: 27090435;

30. Kar SP, Seldin MF, Chen W, Lu E, Hirschfield GM, Invernizzi P, et al. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun. 2013; 14(3):179–86. https://doi.org/10.1038/gene.2013.1 PMID: 23392275;
31. Raikhelson KL, Karev VE, Marchenko NV, Semenov NV, Palgova LK, Baranovsky AY. [Role of transforming growth factor-beta in the development of some liver diseases]. Ter Arkh. 2014; 86(2):44–8. PMID: 24772507.

32. Yokoyama T, Komori A, Nakamura M, Takii Y, Kamihara T, Shimoda S, et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int. 2006; 26(4):467–76. https://doi.org/10.1111/j.1478-3231.2006.01254.x PMID: 16629651.

33. Ray JL, Kopec AK, Joshi N, Cline-Fedewa H, Lash LH, Williams KJ, et al. Trichloroethylene Exposure Reduces Liver Injury in a Mouse Model of Primary Biliary Cholangitis. Toxicological sciences: an official journal of the Society of Toxicology. 2017; 156(2):428–37. https://doi.org/10.1093/toxsci/kfw264 PMID: 28115651;

34. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. Journal of immunology. 2006; 177(3):1655–60. PMID: 16849474.